Alexander Munoz is a Senior Associate at F-Prime and works across the life sciences sub-sectors including therapeutics and medical technology. Prior to joining F-Prime, Alexander was a consultant at Boston Consulting Group, where he focused on biopharma diligence and commercial go-to-market strategy.
Alexander holds an M.D. from the Harvard-MIT Health Sciences & Technology (HST) program and an A.B. in applied mathematics and computer science from Harvard University.
Henry Trapnell joined F-Prime as a Director of Industry Networks to support the firm’s Tech Fund in the U.S. and Eight Roads Ventures abroad. He is a strong believer in the power of community to fuel business growth, and loves connecting portfolio company founders with corporate leaders to build symbiotic partnerships.
Prior to F-Prime, he helped lead digital go-to-market strategy at Google for the company’s hardware & services. He previously advised corporate executives on behalf of J.P. Morgan, where he developed a nuanced understanding of the intersection between emerging technologies, finance, and personal relationships.
Henry graduated from the Stanford Graduate School of Business and studied Economics and Chinese at Boston University. He also serves on the board of the Chestnut Hill Community Association in Philadelphia.
Carolyn Haley joined F-Prime in 2023 where she serves as a Partner, Chief Operating Officer, and Chief Financial Officer and manages the administrative functions of the firm.
Prior to joining F-Prime, Carolyn was a partner and Global Head of Operations and Finance at GMO LLC where she was responsible for the firm’s strategic operating model and led various functions including Operations, Finance, Tax, Corporate Accounting, Enterprise Data Management and Investment Analysis. She also served as President and Trustee of the GMO Trust group of mutual funds, was a member of the Board of Directors for all of the firm’s subsidiaries and a served on several of the firm’s key governance committees, including the ESG and the Diversity, Equity and Inclusion Groups. Prior to GMO, Carolyn was Treasurer and Chief Compliance Officer at Tekla Capital Management (formerly Hambrecht & Quist Capital Management LLC). Prior to that, she was a senior manager with PricewaterhouseCoopers LLP where she served a broad range of clients in the asset management industry.
Ms. Haley earned her bachelor’s degree in Economics and History from Boston University, graduating magna cum laude, and her Masters of Science in Accounting from the Isenberg School of Management at the University of Massachusetts, Amherst. She is a Certified Public Accountant.
Anya Gorny joined F-Prime/FBRI in January of 2023. She is the Executive Assistant to the President of FBRI, Stacie Weninger, Ph.D. Before coming to F-Prime/FBRI, Anya worked as the Executive Assistant for the leadership team at ASAP.com. Prior to ASAP.com, Anya supported the President of The Kraft Group as an Administrative Assistant for five years. Anya received her BA in Communications from the University of New Hampshire.
Dr. John Shiver is a Special Advisor for F-Prime and is also Chief Strategy Officer at IGM ID a wholly owned subsidiary of IGM Biosciences. Established in 2021, IGM ID utilizes a proprietary IgM platform to treat and prevent infectious diseases. The potential utility of this platform for prevention and treatment of infectious diseases is supported by its recent application towards COVID-19 (Ku et al., Nature, published online 03 June 2021).
Prior to joining IGM ID, John was the SVP and Global Head of Vaccines R&D and a member of the Executive Leadership team for 8 years at Sanofi Pasteur, the largest company in the world devoted entirely to vaccines. He previously spent 22 years at Merck & CO where he held a series of senior leadership positions with his last position being VP and Head of Vaccines and Biologics Research. He was a member of Merck Vaccines Integrated Leadership Team and the Global Research Leadership Committee responsible for vaccine research, vaccine clinical assays and biomarkers, and biologics research, and siRNA technologies. Earlier in his career John spent five years at the National Cancer Institute, National Institutes of Health in Bethesda, MD.
John is a recognized expert and industry leader in vaccine and pharmaceutical research and development. He has guided numerous scientific teams that created novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including HIV, influenza, HPV, RSV, CMV, pneumococcus, cancer, and asthma. He has collaborated with other senior leaders to secure the licensure of 14 pharmaceutical products spanning both vaccines and monoclonal antibodies, many of which were first- and/or best-in-class products addressing global infectious diseases. He also championed four acquisitions and three major collaborations to obtain new technologies or clinical candidates/products.
John is a Fellow of the American Academy of Microbiology and the International Society of Vaccines (ISV) and a member of multiple advisory boards, including the Board of Directors for the International AIDS Vaccine Initiative (IAVI), Board of Directors for Icosavax, and previously, the Executive Board of the International Society for Vaccines. He has also served on journal editorial boards, including Nature Partner Journals Vaccines and the Journal of Virology. He is the author of more than 150 articles, including 19 in Science, Nature, Cell, and the Proceedings of the National Academy of Sciences and is a co-author of 68 awarded patents. In addition, he is an Adjunct Professor at the University of Pennsylvania College of Medicine and has been recognized by the Financial Times.
John holds a Ph.D. in Physical Chemistry from the University of Florida in Gainesville, FL and completed a postdoctoral fellowship in Biophysics at Purdue University in West Lafayette, IN. He also holds a Bachelor of Science degree in Chemistry and Mathematics from Wofford College in Spartanburg, SC.
Jillian Enos is Senior Director of Finance and joined F-Prime in April 2022. Prior to joining F-Prime, she worked at Charlesbank Capital Partners where she held the position of Valuations and Portfolio Reporting Manager. Jill also worked at PwC for six years, most recently as a Manager in their Assurance practice, where she was primarily focused on private equity and private credit fund clients.
Jill earned her BBA in Accounting from the Isenberg School of Management at University of Massachusetts, Amherst and is a certified public accountant in the state of Massachusetts.
Andrew Bognanni joined F-Prime in April 2022 to assist the finance and operations teams at the firm. Prior to joining F-Prime, he was employed by Standish Management where he held the position of Manager. He also worked at RSM in their audit practice. Andrew holds a M.S. in Accounting from Northeastern University.
Joshua Gray is Vice President and Associate General Counsel at Fidelity Investments and supports the F-Prime team on legal aspects of the firm’s operations, including portfolio company investments and exits, fund formation, ongoing fund administration, and day-to-day management company operations.
Josh joined Fidelity in 2022 from Nutter McClennen & Fish, where he was a Partner and a member of the Corporate and Transactions department. Josh also previously worked as an associate in the Technology and Life Sciences groups of the international law firm Goodwin Procter. He has over a decade of legal experience counseling venture capital and private equity firms, public and private companies, and entrepreneurs on a variety of matters, including company formation, equity and debt financings, mergers and acquisitions, strategic alliances, public offerings, securities law matters, corporate governance, intellectual property transactions, employment and equity compensation matters, and other general business matters. Over the course of his career, Josh has worked across a broad spectrum of industries, including life sciences, health care, medical devices, software, information technology, consumer goods and financial services.
Josh received his B.A., cum laude, from Syracuse University and his J.D. from New York University School of Law, where he was an Editor of the New York University Environmental Law Journal.
Josh is admitted to the Massachusetts bar.
Am is a Data Scientist for F-Prime’s tech fund, where he focuses on data science, automation and Enterprise IT. Prior to joining F-Prime, Am worked as a Data Scientist for John Hancock Investments where he helped develop models to predict why and when Financial Advisors would buy a specific financial product. Early in his career, Am worked at the Bollyky Lab at the Stanford Medical School where he worked as part of the team to analyze and predict T-Cell behavior for the paper: Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection.
Am holds a B.S. degree from Northeastern University where he majored in Computer Engineering specializing in ML, Computer Vision, and Algorithms.
Jackson Wilkinson is a Venture and Operating Partner with F-Prime, based in the Cambridge office. Jackson supports and advises early-stage healthcare and technology portfolio companies, getting hands-on to help accelerate early product, design, and engineering efforts.
Jackson has led product development at a variety of software companies. Most recently, he was Chief Technology Officer of Project Beacon COVID-19, rapidly expanding access to testing during the pandemic. Previously, he was Senior Vice President at PathAI and led product, design, and engineering, helping grow the company and its technology platform from seed stage through its Series B. Jackson was co-founder and CTO of Kinsights, and following its acquisition, led product and design as part of the management team at Care.com. Prior to his work in digital health and health tech, Jackson led design and UX efforts at consumer technology companies including Posterous (acquired by Twitter) and LinkedIn.
Jackson is a graduate of Bowdoin College, where he holds a degree cum laude in Music and Philosophy.